GPBAR1; | |
TSHR; | |
PTPN1; PTPN2; PTPRF; ACP1; | |
ALPI; RECQL; GLA; FAAH; TDP1; P4HB; TERT; GLO1; HSD11B1; AKR1B1; HSD17B10; ALOX12; AKR1B10; NOX4; ALOX15; TNKS; PARP1; TNKS2; POLB; CD38; | |
GAA; | |
GSK3B; FLT3; | |
CA2; CA1; CA12; CA9; CA5B; CA14; CA7; CA5A; CA4; CA6; CA3; | |
PPARA; PPARG; PPARD; | |
RORC; | |
ESR1; ESR2; | |
NR1H4; | |
ALOX5; MAOA; XDH; | |
KDM4E; | |
MMP1; MMP12; MMP2; MMP9; | |
TLR2; | |
HIF1A; TP53; NFKB1; | |
ABCG2; | |
HTT; LMNA; FABP2; FABP4; MAPT; FABP5; FABP3; APP; TTR; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 7.527E-10 | 4.203E-07 | AKR1B1, AKR1B10, ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, GAA, GSK3B, HSD11B1, HSD17B10, KDM4E, MAOA, NOX4, P4HB, PPARD, PPARG, XDH |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.417E-08 | 1.200E-05 | AKR1B1, AKR1B10, APP, CYP1A1, CYP1A2, CYP1B1, ESR1, HSD11B1, NR1H4, PPARD |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 6.578E-07 | 1.488E-04 | ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG, RORC |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.130E-06 | 2.344E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.362E-06 | 4.433E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.650E-06 | 4.692E-04 | ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG, RORC |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.650E-06 | 4.692E-04 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, XDH |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.901E-06 | 5.094E-04 | HIF1A, LMNA, P4HB, PPARD, TERT, TP53 |
BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 3.988E-06 | 6.579E-04 | ABCG2, AKR1B1, CA3, CA9, CD38, CYP1A1, CYP1B1, FABP3, NFKB1, POLB, PPARG, TLR2, TP53 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 4.797E-06 | 7.737E-04 | ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG, RORC |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.203E-06 | 8.331E-04 | NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.773E-06 | 8.980E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.353E-06 | 9.674E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.622E-06 | 1.153E-03 | APP, CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4, PPARG, RORC |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.421E-06 | 1.231E-03 | ABCG2, APP, CD38, ESR1, ESR2, FLT3, GLA, HTT, MAPT, MMP9, NFKB1, PARP1, PPARG, SMN1, SMN2, TERT, TP53, TTR, XDH |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 8.712E-06 | 1.256E-03 | GSK3B, HTT, MAPT |
BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 1.152E-05 | 1.587E-03 | AKR1B1, ALOX15, APP, CA2, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP5, FLT3, GAA, GSK3B, HIF1A, HSD11B1, HTT, LMNA, MMP9, POLB, PPARA, PPARD, PPARG, PTPRF, RORC, SMN1, SMN2, TLR2, TP53, TSHR |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.448E-05 | 1.888E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.448E-05 | 1.888E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.448E-05 | 1.888E-03 | ALOX12, ALOX15 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.968E-05 | 2.449E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 2.376E-05 | 2.846E-03 | TERT, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 2.454E-05 | 2.895E-03 | AKR1B10, CYP1A1, CYP1B1, PPARD, TTR |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.459E-05 | 2.895E-03 | ALOX15, ESR1, GSK3B, MAPT, MMP1, PARP1, TP53 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.530E-05 | 2.946E-03 | CA2, CA7, HIF1A, HTT, NR1H4, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.625E-05 | 3.009E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.916E-05 | 3.290E-03 | ALOX12, ALOX15, ALOX5 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.531E-05 | 3.788E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0051179; localization | GO:0046903; secretion | 3.703E-05 | 3.916E-03 | ALOX5, APP, CA2, CA9, FABP5, GAA, GLA, HIF1A, MMP9, NFKB1, NR1H4, TLR2, TTR, XDH |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 4.333E-05 | 4.266E-03 | APP, TLR2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.333E-05 | 4.266E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 4.333E-05 | 4.266E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.333E-05 | 4.266E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.333E-05 | 4.266E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 4.333E-05 | 4.266E-03 | GPBAR1, NR1H4 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 5.397E-05 | 5.154E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 5.429E-05 | 5.162E-03 | NOX4, PARP1, POLB, TP53 |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 5.871E-05 | 5.395E-03 | ESR1, PPARA, TERT |
BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 5.901E-05 | 5.399E-03 | AKR1B1, CYP1A1, CYP1B1, ESR1, TTR |
BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 6.205E-05 | 5.653E-03 | AKR1B1, CA9, CD38, PARP1, PPARG, TLR2 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 6.782E-05 | 6.047E-03 | ALOX12, APP, CD38, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PPARD, PPARG, PTPN2, TERT, TLR2, XDH |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.831E-05 | 6.047E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 7.888E-05 | 6.733E-03 | HIF1A, TERT, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 7.888E-05 | 6.733E-03 | MMP2, MMP9, TERT |
BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 7.916E-05 | 6.733E-03 | AKR1B1, ALOX15, APP, CYP1B1, FLT3, HTT, NOX4, PPARD, PTPN1, PTPN2, TLR2, TP53, XDH |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.167E-05 | 6.867E-03 | CA2, CA7, CD38, HIF1A, HTT, NR1H4, PARP1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.644E-05 | 7.024E-03 | TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 8.644E-05 | 7.024E-03 | PTPN1, PTPN2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 8.644E-05 | 7.024E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.644E-05 | 7.024E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 8.644E-05 | 7.024E-03 | ESR1, ESR2 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.046E-05 | 7.296E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.046E-05 | 7.296E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.031E-04 | 7.933E-03 | CYP1A1, CYP1A2, PPARG |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.039E-04 | 7.965E-03 | CYP1B1, GSK3B, HTT, MAPT, MMP9, NOX4, PPARG, PTPN2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0016311; dephosphorylation | 1.070E-04 | 8.179E-03 | ACP1, ALPI, CA3, POLB, PTPN1, PTPN2, PTPRF |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.126E-04 | 8.514E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.168E-04 | 8.659E-03 | HIF1A, PPARD, TP53 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.267E-04 | 9.296E-03 | FABP3, PPARA, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.317E-04 | 9.529E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.343E-04 | 9.648E-03 | HIF1A, NFKB1, PPARA, PTPN2 |
BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 1.343E-04 | 9.648E-03 | CD38, HIF1A, NR1H4, PPARD |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.616E-24 | 1.759E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.371E-19 | 4.557E-15 | ALPI, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, MMP1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, PPARD, PPARG, PTPN1, RORC, TNKS, TP53 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.323E-18 | 3.625E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.493E-17 | 2.642E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.936E-24 | 1.530E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.661E-10 | 1.279E-08 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.966E-06 | 1.009E-04 | GSK3B; FLT3; MMP1; MMP2; PPARG; HIF1A; TP53; MMP9; NFKB1; PPARD |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.426E-05 | 4.046E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.399E-06 | 1.694E-04 | AKR1B10; GAA; AKR1B1; GLA |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.576E-05 | 4.046E-04 | MMP1; MMP2; MMP9; TP53 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.237E-05 | 1.078E-03 | PTPN1; GSK3B; PPARA; NFKB1; PTPRF |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.962E-05 | 1.078E-03 | APP; MAOA; ALOX5; ALOX15; ALOX12 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.060E-04 | 1.632E-03 | MMP2; TP53; HIF1A; ESR1; MMP9; TLR2 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.566E-04 | 1.723E-03 | MAOA; GAA; ALOX15; AKR1B1; ALOX12; HSD17B10; HSD11B1; AKR1B10; ALOX5; CYP1A2; CYP1A1; CD38; ALPI; XDH |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.469E-04 | 1.723E-03 | GSK3B; ESR1; NFKB1; ESR2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.297E-05 | 1.078E-03 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.549E-04 | 1.723E-03 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.984E-04 | 4.797E-03 | MMP2; ESR1; MMP9; ESR2 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.428E-04 | 2.493E-03 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.446E-04 | 4.934E-03 | FLT3; PPARG; TP53; MMP9; NFKB1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.637E-04 | 7.811E-03 | GSK3B; TP53; ESR1; HIF1A |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.411E-04 | 7.196E-03 | ALOX5; CYP1A1; CYP1B1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.501E-03 | 1.045E-02 | GSK3B; PPARA; TP53; NFKB1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.233E-03 | 9.491E-03 | FLT3; NFKB1; PPARD |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.811E-03 | 1.073E-02 | PARP1; LMNA; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.629E-03 | 1.045E-02 | GSK3B; TP53; NFKB1; TLR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.110E-03 | 1.161E-02 | TP53; MMP9; NFKB1; TLR2 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.362E-03 | 9.990E-03 | AKR1B10; AKR1B1; GLA |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.683E-03 | 1.333E-02 | POLB; GSK3B; TERT; TP53; NFKB1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.572E-03 | 1.045E-02 | ALOX5; ALOX15; ALOX12 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.802E-03 | 1.073E-02 | RORC; NFKB1; TLR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.965E-03 | 1.121E-02 | FLT3; TP53; HIF1A |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.500E-03 | 1.634E-02 | APP; GSK3B; MAPT; HSD17B10 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.611E-03 | 1.333E-02 | PTPN1; ACP1; PTPRF |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.397E-03 | 1.991E-02 | GSK3B; TP53; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.320E-03 | 1.232E-02 | CA2; NR1H4; ABCG2 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.122E-03 | 2.139E-02 | PPARG; TP53; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.701E-03 | 2.580E-02 | GSK3B; CD38; TP53; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.575E-03 | 3.511E-02 | ALOX5; NFKB1; TLR2 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.002E-02 | 3.589E-02 | GSK3B; TP53; NFKB1 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.420E-02 | 4.969E-02 | MAOA; NFKB1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.140E-03 | 2.139E-02 | PPARG; TP53 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.140E-03 | 2.139E-02 | CYP1A2; ALOX15 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 6.235E-03 | 2.527E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 7.844E-03 | 2.946E-02 | AKR1B10; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.621E-03 | 2.580E-02 | POLB; PARP1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.249E-03 | 1.564E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.341E-04 | 1.723E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; MMP1; AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2; TERT; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; PPARD; NFKB1; PPARG; PPARG |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; HSD11B1; PPARD; MMP12 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; MMP1 |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
NA: NA | Edema | NA | CA2 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; TLR2; MMP2; MMP9 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR; APP |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
NA: NA | Dyslipidemia | NA | PPARD |
C00-D49: Neoplasms | CLL | NA | FLT3 |
NA: NA | GIST | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PPARG |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; TERT; ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; FAAH |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
C00-D49: Neoplasms | Glioma | C71 | APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOA; MAPT; APP; PPARG; PPARG |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; HSD11B1; HSD11B1; AKR1B1; PPARG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
C00-D49: Neoplasms | AML | NA | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH; ESR1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; TERT; MMP2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; PARP1; MMP2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12; FAAH |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD; PPARG |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; HIF1A; TP53; CA1; FLT3; FLT3; CA9; NFKB1; TLR2; PARP1; MMP2; MMP9; ESR1; ESR1; APP; CD38 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |